MedTrace Logo

Multihance at 3 Tesla (3T) in Brain Tumors

NCT00395863 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2020-11-05

Study results available
· View outcomes & findings →

Summary

Compare the efficacy of MultiHance and Magnevist

Conditions

Interventions

DRUG

Multihance

0.5 M at a single injection

DRUG

Arm 2 - Magnevist

0.5 M Magnevist at a single dose injection

Sponsors & Collaborators

  • Bracco Diagnostics, Inc

    lead INDUSTRY

Principal Investigators

  • Gianpaolo Priovano, M.D. · Bracco Diagnostics, Inc

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2008-02-29
Completion
2008-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00395863 on ClinicalTrials.gov